medRxivGenetic & Genomic MedicinePreprint
MDSGene update and expansion: Clinical and genetic spectrum of LRRK2 variants in Parkinson's disease
Clara Krüger, Shen‐Yang LimiD, Alissa Buhrmann, Fenja L. FahrigiD, Carolin GabbertiD, Natascha BahriD, Harutyun MadoeviD, Connie MarrasiD, Christine KleiniD, Katja LohmanniD
Abstract
Pathogenic variants in the LRRK2 gene are one of the most commonly identifiable monogenic causes of Parkinso[n]s disease (PD, PARK-LRRK2). This systematic MDSGene literature review comprehensively summarizes published demographic, clinical, and genetic findings related to potentially pathogenic LRRK2 variants (https://www.mdsgene.org/). Recent insights on LRRK2s kinase activity have been incorporated for pathogenicity scoring. Data on 7,885 individuals with 292 different variants were curated, including 3,296 patients with PD carrying 205 different potentially disease-causing LRRK2 variants. The initial MDSGene review covered only 724 patients carrying 23 different LRRK2 variants. Missingness of phenotypic data in the literature was high, hampering the identification of detailed genotype-phenotype correlations. Notably, the median age at onset in the patients with available information was 56 years, with approximately one-third having PD onset 80% of patients, with Tunisia, Spain, and Italy contributing about half of patients. This systematic review represents the largest database on PARK-LRRK2 to date and provides an important resource to improve precision medicine. Given their high frequency, a better interpretation of the pathogenicity of VUS is needed for selection and stratification of patients in clinical trials.
- organism: human
- assay: GWAS summary statistics
- research focus: database / resource
- approach: statistical model
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Negative screening for 12 rare LRRK2 pathogenic variants in a cohort of Nigerians with Parkinson disease
Mie Rizig, Oluwadamilola Omolara Ojo, … Njideka Ulunma Okubadejo·Neurobiology of AgingPeer-reviewed·Oct 1, 2020
- Functional analyses of two novel LRRK2 pathogenic variants in familial Parkinson's disease
Ilda Coku, Eugénie Mutez, … Vincent Huin·Movement DisordersPeer-reviewed·Jun 16, 2022
- Parkinson's disease-associated LRRK2 risk variant, G2385R, enhances Rab substrate phosphorylation and impairs neuronal integrity
An Phu Tran Nguyen, Roger Moser, … Darren J. Moore·Human Molecular GeneticsPeer-reviewed·Jan 1, 2026
- Genome-wide association studies of LRRK2 modifiers of Parkinson's disease
Dongbing Lai, Babak Alipanahi, … Tatiana Foroud·Annals of NeurologyPeer-reviewed·May 3, 2021
- LRRK2 exonic variants associated with Parkinson’s disease augment phosphorylation levels for LRRK2-Ser1292 and Rab10-Thr73
Kenneth V. Christensen, Morten Hentzer, … Garrick P. Smith·bioRxiv·Oct 22, 2018
- Impact of 100 LRRK2 variants linked to Parkinsons Disease on kinase activity and microtubule binding
Alexia F. Kalogeropulou, Elena Purlyte, … Dario R. Alessi·Biochemical JournalPeer-reviewed·Aug 11, 2022